Bloody diarrhea and a positive screen for Stx2 were used as inclusion criteria, as these factors have been identified as risk factors for STEC-HUS development and were thought to serve to enrich the patient population within the study with those most likely to benefit from this therapy. Here, STX2 is linked to hemolytic-uremic syndrome.